Screener
Iovance Biotherapeutics, Inc. IOVA Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 2,673 | 4,043 |
| Total Current Liabilities | 106,848 | 138,358 |
| Non-Current Liabilities | ||
| Operating lease liabilities – non-current | 43,330 | 44,401 |
| Deferred tax liabilities | 29,308 | 31,828 |
| Total Non-Current Liabilities | 72,638 | 76,229 |
| Total Liabilities | 179,486 | 214,587 |
| Commitments and contingencies |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s operating lease liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease liabilities of $43.33M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease liabilities decreased by 3.9% year-over-year, from $45.1M to $43.33M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease liabilities has grown at a -0.4% compound annual growth rate (CAGR), from $45.38M to $44.4M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude